FDA/CMS Parallel Review: Firms Lack Incentive To Participate, Lawyers Say
Executive Summary
As drug industry advisors scrutinize FDA’s and CMS’ recent proposal to institute voluntary parallel reviews of new medical products, some are seeing little reason for manufacturers to subject their products to parallel review.
You may also be interested in...
Comparative Evidence Needs Earlier Consideration In Drug Development Process – Novartis Exec
As comparative effectiveness research grows in importance, drug manufacturers need to factor it, as well as payer evidence needs, into product development decisions, Novartis Head of Comparative Effectiveness Research and Communications Amy Rudolph says.
IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts
BALTIMORE – Decisions by the soon-to-be-created Independent Payment Advisory Board could make CMS participation in parallel review of drugs with FDA much more meaningful than it would otherwise be, assuming the health care reform law remains intact, former CMS and FDA official Scott Gottlieb said.
IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts
BALTIMORE – Decisions by the soon-to-be-created Independent Payment Advisory Board could make CMS participation in parallel review of drugs with FDA much more meaningful than it would otherwise be, assuming the health care reform law remains intact, former CMS and FDA official Scott Gottlieb said.